GeneDx is trading 4.8% up at $63.47 as it extends its recovery following sharp post-earnings volatility earlier this quarter.
- The move appears to reflect continued recovery and positioning after prior Q1 and Fabric-related disclosures rather than a new catalyst.
- There are no fresh company-specific news or filings reported for July 28, 2026.
- The stock's gain comes despite mixed broader market indices and slight weakness in the biotech sector.